The Committee for Human Use (CHMP) of the EMA has begun the review of Buflomedil.
The Board will take the risk of cardiac and neuronal toxicity, especially after overdose in patients Buflomedil for the treatment of peripheral arterial occlusive disease.
Source:
Press release of 18 EMA February 2011
0 comments:
Post a Comment